INVESTOR MEETING ASTRO 2013
|
|
- Kory Welch
- 5 years ago
- Views:
Transcription
1 INVESTOR MEETING ASTRO 2013 Webcast will begin 7:15 a.m. EDT SEPTEMBER 24, VARIAN MEDICAL SYSTEMS. ALL RIGHTS RESERVED.
2 Forward-Looking Statements Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of Statements concerning industry outlook, including growth drivers; the company s future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology such as TrueBeam, EDGE and radiographic flat panel detectors, image-guided radiation therapy, stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection, and any statements using the terms could, believe, outlook, or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company s actual results to differ materially from those anticipated. Such risks and uncertainties include global economic conditions; the impact of the Affordable Health Care for America Act (including excise taxes on medical devices) and any further health care reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; currency exchange rates and tax rates; demand for the company s products; the company s ability to develop, commercialize, and deploy new products such as the TrueBeam and EDGE platforms; the company s ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; challenges associated with the successful commercialization of the company s particle therapy business; the effect of adverse publicity; the company s reliance on sole or limited-source suppliers; the impact of reduced or limited demand by purchasers of certain X-ray products, including those located in Japan; the company s ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges to public tender awards and the loss of such awards or other orders; and the other risks listed from time to time in the company s filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise. 2 INVESTOR MEETING - ASTRO 2013
3 Agenda Welcome Dow Wilson, Chief Executive Officer Oncology Megatrends Kolleen Kennedy, Senior Vice President; President, Oncology Systems Clinical Advances Dr. Deepak Khuntia, Vice President, Medical Affairs 3 INVESTOR MEETING - ASTRO 2013
4 4 INVESTOR MEETING - ASTRO 2013
5 5 INVESTOR MEETING - ASTRO 2013 Thank you
6 6 INVESTOR MEETING - ASTRO 2013
7 7 INVESTOR MEETING - ASTRO 2013
8 8 INVESTOR MEETING - ASTRO 2013
9 9 INVESTOR MEETING - ASTRO 2013
10 10 INVESTOR MEETING - ASTRO 2013
11 ONCOLOGY MEGATRENDS Kolleen Kennedy, Senior Vice President; President, Oncology Systems 2013 VARIAN MEDICAL SYSTEMS. ALL RIGHTS RESERVED.
12 Overview Varian is the global radiotherapy leader Long-term demand for radiotherapy is increasing Healthcare megatrends drive our strategy for continued leadership and market expansion 12 INVESTOR MEETING - ASTRO 2013
13 13 INVESTOR MEETING - ASTRO 2013
14 Who We Are 6,300 employees $2.8B sales 3,000 software installs 7,000 medical linear accelerators 30,000 X-ray tubes 14 INVESTOR MEETING - ASTRO 2013
15 7,000 Varian Accelerators 60% of global installed base 2.8M patients treated annually 15 INVESTOR MEETING - ASTRO 2013
16 Oncology Megatrends Demographics Global Markets Minimally Invasive Digital Frontier Personalized Medicine 16 INVESTOR MEETING - ASTRO 2013
17 Add photo here of Varian employees Demographics 17 INVESTOR MEETING - ASTRO 2013
18 Global Cancer Burden Rising 27 million people The global cancer burden by 2050 is expected to grow to 27 million new cancer cases and 17.5 million deaths.* *American Cancer Society, Global Cancer Facts and Figures, INVESTOR MEETING - ASTRO 2013
19 Cancer in Women #1: Liver #1: Breast #1: Lung #1: Uteri Number 1 cancer incidence per 100,000, age normalized Sources: American Cancer Society, Globocan data 19 INVESTOR MEETING - ASTRO 2013
20 Cancer In Men #1: Lung #1: Liver #1: Stomach #1: Prostate Number 1 cancer incidence per 100,000, age normalized Sources: American Cancer Society, Globocan data 20 INVESTOR MEETING - ASTRO 2013
21 Worldwide Demographic Shift 1,600 1,400 1,200 1, Source: U.S. Census Bureau People 60 Years and Older in Millions +82% BRIC +97% Other BRIC NA EU Developed 21 INVESTOR MEETING - ASTRO 2013
22 22 INVESTOR MEETING - ASTRO 2013 Global Markets
23 10,000 Linacs Needed Radiotherapy Machines per Million People Over 64 Years * Machines include Linac and Cobalt Units Source: IAEA and World Health Organization 23 INVESTOR MEETING - ASTRO 2013
24 China Investing in Radiation Oncology 14% projected CAGR Units ~16% Patients Treated With RT Source: IPSOS database and analysis 24 INVESTOR MEETING - ASTRO 2013
25 Varian Investing in China Users Meeting 525 Customers 25 INVESTOR MEETING - ASTRO 2013
26 US Market Varian -- 68% of linac installations 38% sites plan to buy Source: IMV 2012/2013 Radiation Therapy Market Survey 26 INVESTOR MEETING - ASTRO 2013
27 USA Demand Rising Aging Population SRS/SBRT Healthcare Reform 27 INVESTOR MEETING - ASTRO 2013
28 Number of units USA Installed Base Aging 1,200 1, <5 years <5 5~9 5-9 Years 10~ Years 15~ Years >20 >20 Years Age in years 28 INVESTOR MEETING - ASTRO 2013
29 Varian Offers Broadest Capability Novalis Tx Neurosurgical and Radiosurgical Applications TrueBeam /TrueBeam STx Treatment Procedures with Ease, Speed and Accuracy Trilogy All-in-one Treatment System Clinac Versatile Treatment Platform UNIQUE Cost Effective Oncology Solution* Eclipse Treatment Planning System * Not for available for sale in all markets Cancer Treatment Advanced Radiotherapy IMRT, IGRT, RapidArc Brachy Therapy Radio Surgery ARIA Oncology Information System Proton Therapy Calypso Real-Time Tracking Technology* ProBeam Proton Therapy Systems Varian Brachytherapy Product Suite for Planning and Delivery EQUICARE CS Survivorship* Edge System Dedicated full-body Radiosurgery Platform* 29 INVESTOR MEETING - ASTRO 2013
30 Varian Addressing Market Gaps Equipment & Resources Training Experience Skills / Expertise Knowledge / Theory 30 INVESTOR MEETING - ASTRO 2013
31 Add photo here of Varian employees Minimally Invasive 31 INVESTOR MEETING - ASTRO 2013
32 Radiosurgery SRS/SBRT Surgery without a trace 32 INVESTOR MEETING - ASTRO 2013
33 330 Radiosurgery Adoption Rising SRS/SBRT National Forecast US Adult Market, , in thousands % increase projected Source: SG2 Consulting, Skokie, Illinois, U.S. 33 INVESTOR MEETING - ASTRO 2013
34 Lung Leading Expansion Projected 10-Year Growth in SRS/SBRT Radiosurgery O Lung Brain/CNS 0 20K 40K 60K 80K Prostate GI Bone mets Head and Neck 140% increase in lung procedures Source: SG2 Consulting, Skokie, Illinois, U.S. 34 INVESTOR MEETING - ASTRO 2013
35 The Edge Radiosurgery Suite 35 INVESTOR MEETING - ASTRO 2013
36 36 INVESTOR MEETING - ASTRO 2013 Digital Advances
37 Digital Advances Mobility Telemedicine Big Data Decision Support 37 INVESTOR MEETING - ASTRO 2013
38 Digital Advances With you every step of the way from diagnosis to survivorship 38 INVESTOR MEETING - ASTRO 2013
39 Introducing RapidPlan Improving Quality and Speed of Treatment Planning Beginner Increase Confidence Good starting point Experienced Improve Consistency Clinician skills & experience Busy clinics Increase Efficiency Clinical trials Increase Participation Increase Consistency 510(k) Pending not available for sale 39 INVESTOR MEETING - ASTRO 2013
40 RapidPlan -- How it Works Patient Case Share cases with colleagues. Improve quality of care globally. New patient Reference case match Reference Case Add to Knowledge Base Auto contour Local Knowledge Base Contours morphed from Expert Case Evaluate against prior experience Auto Evaluation Auto plan Target Cord Parotid IMRT Dose distribution derived from prior experience 510(k) Pending not available for sale
41 Knowledge-Based Planning Best practice models for IMRT, RapidArc, and SBRT More efficient creation of high-quality treatment plans Ability to create practice standards 41 INVESTOR MEETING - ASTRO 2013
42 Oncology Continuum Solutions Solution Categories Data- and analyticsbased solutions for multiple segments Population Health Management Comparative Effectiveness Translation Medicine Safety and Surveillance $2.3B market opportunity Platform-based software solutions targeted at providers Decision Support Care Coordination Care Delivery 42 INVESTOR MEETING - ASTRO 2013
43 Add photo here of Varian employees Personalized Medicine 43 INVESTOR MEETING - ASTRO 2013
44 Personalized Medicine Targeted Therapies Molecular Imaging Genomics Patient Self-Care Equicare 44 INVESTOR MEETING - ASTRO 2013
45 Treatment Paradigm: Genetic profiling & population based analytics Earlier diagnosis leads to improved outcomes Precision medicine enabled by innovation Cloud-based collaboration drives global best practices Survivorship programs thrive 45 INVESTOR MEETING - ASTRO 2013
46 Key Strategies Innovation Globalization Software Leadership Comprehensive Services Operational Excellence 46 INVESTOR MEETING - ASTRO 2013
47 Summary Varian is the global radiotherapy leader Long-term demand for radiotherapy is increasing Healthcare megatrends drive our strategy for continued leadership and market expansion 47 INVESTOR MEETING - ASTRO 2013
48 CLINICAL ADVANCES AND FUTURE OPPORTUNITIES IN RADIOTHERAPY Dr. Deepak Khuntia, Vice President, Medical Affairs Varian Medical Systems 2013 VARIAN MEDICAL SYSTEMS. ALL RIGHTS RESERVED.
49 Highlights of the Last Decade Multileaf Collimators (MLC) On-Board Imager (OBI) High Definition MLC RADIOSURGERY SUITE 49 INVESTOR MEETING - ASTRO 2013
50 Brain Stereotactic Radiosurgery Survival in patients with single metastasis Survival by treatment unit Patients receiving SRS boost live longer versus traditional radiation alone Linac and Cobalt SRS equivalent The Lancet, Vol. 363, May 22, INVESTOR MEETING - ASTRO 2013
51 Prostate SBRT on the Rise! ASTRO SBRT MODEL POLICY 4/17/2013 It is ASTRO s opinion that data supporting the use of SBRT for prostate cancer have matured to a point where SBRT could be considered an appropriate alternative for select patients with low to intermediate risk disease. 51 INVESTOR MEETING - ASTRO 2013
52 Head and Neck Cancer: Targeted Drugs Improve RT Outcome Median survival rises from 14.9 months to 24.4 months Radiotherapy plus Cetuximab for Squamous- Cell Carcinoma of the Head and Neck Post Thoracic Surgery Neuropathy Source: Bonner et al, Courtesy NEJM, 345;6, of Paul Feb. Harari, 9, 2006 MD 52 INVESTOR MEETING - ASTRO 2013
53 Advanced IMRT: Sparing Memory Even low doses to hippocampus damages memory Avoiding hippocampus preserves memory Kempermann & Neumann Science 302: 1689 (2003) 53 INVESTOR MEETING - ASTRO 2013
54 Hippocampal Sparing Whole Brain RT Black area: Hippocampus Red contour: Hippocampal avoidance region Gondi et al. IJROBP.Vol 78, No. 4, pp , 2010 Gondi et al. ASTRO 2013 Plenary Session 54 INVESTOR MEETING - ASTRO 2013
55 SBRT Now Being Used for Pancreas! 55 INVESTOR MEETING - ASTRO 2013
56 Radiation Medicine: New Opportunities Emphysema Cardiac Arrhythmia (atrial fibrillation) Depression Post Thoracic Surgery Neuropathy Plantar Fascitis 56 INVESTOR MEETING - ASTRO 2013
57 Arrhythmia: A Non-invasive Approach Normal Sinus Rhythm Atrial Fibrillation 57 INVESTOR MEETING - ASTRO 2013
58 Functional Disorders: A Hopeful Outlook? Pioneering Work in: Epilepsy OCD Depression Cluster headaches 58 INVESTOR MEETING - ASTRO 2013
59 QUESTIONS AND ANSWERS 2013 VARIAN MEDICAL SYSTEMS. ALL RIGHTS RESERVED.
60 60
Annual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationJP MORGAN HEALTHCARE CONFERENCE DOW R. WILSON President and Chief Executive Officer 1 FOR INVESTOR USE ONLY
JP MORGAN HEALTHCARE CONFERENCE - 2017 DOW R. WILSON President and Chief Executive Officer 1 FOR INVESTOR USE ONLY THIS PRESENTATION IS INTENDED EXCLUSIVELY FOR INVESTORS. IT IS NOT INTENDED FOR USE IN
More informationJanuary 2018 Dow Wilson President and Chief Executive Officer
J.P. Morgan 2018 Healthcare Conference January 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing.
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationFuture of Radiation Therapy
Future of Radiation Therapy JP Morgan Healthcare Conference January 12, 2016 Deepak Khuntia, MD, VP of Medical Affairs Patrick Kupelian, MD, VP of Clinical Affairs Cancer as a cause of death CANCER TREATMENT
More informationGlobal Radiation Therapy Market Report
Global Radiation Therapy Market Report ----------------------------------------- 2013 Executive Summary Radiotherapy is used to kill cancerous cells and is commonly used either alone or in combination
More informationJefferies Healthcare Conference
Jefferies Healthcare Conference Jean-Marc BOTHY - CSO June 8, 2017 2017 IBA SA Disclaimer This presentation may contain forward-looking statements concerning industry outlook, including growth drivers;
More information7/30/2017. One World Medical Physics: Challenges and Opportunities in Cancer Care. Worldwide Demographic Shift
People 60 Years and Older ( in Millions) 7/30/2017 One World Medical Physics: Challenges and Opportunities in Cancer Care Jatinder R Palta PhD, FAAPM, FASTRO, FACR Virginia Commonwealth University, and
More informationElekta Synergy Digital accelerator for advanced IGRT
Elekta Synergy Digital accelerator for advanced IGRT Setting the standard for confident care The Field of Radiation Therapy is Constantly Changing Being able to take full advantage of the latest clinical
More informationElekta - a partner and world-leading supplier
Experience Elekta Elekta - a partner and world-leading supplier of clinical solutions for image guided radiation therapy, stereotactic radiotherapy, radiosurgery and brachytherapy, as well as advanced
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationBRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationSAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report
More informationVarian and BrainLAB this historically strong relationship has evolved and is set to unlock infinite possibilities Varian Medical Systems, the world s leading manufacturer of radiotherapy and radiosurgery
More informationEconomic Implications of Advancements in Radiation Technology. Dramatic Growth of RT Capacity in the US
Economic Implications of Advancements in Radiation Technology Sponsored by: OTN Anthony M. Berson, M.D. Radiation Oncology, St. Vincent s Comprehensive Cancer Center Richard Emery Vice President, Aptium
More informationThe TomoTherapy System as a Tool of Differentiation in Quality and Marketability
The TomoTherapy System as a Tool of Differentiation in Quality and Marketability John J. Kresl, MD, PhD, FACRO, FACR Medical Director Phoenix CyberKnife & Radiation Oncology Center Managing Partner Phoenix,
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationImportant information
Important information This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationMedSurg: Endoscopy Presentation for the Investment Community at DDW. Art Butcher Senior Vice President and President, Endoscopy
MedSurg: Endoscopy Presentation for the Investment Community at DDW Art Butcher Senior Vice President and President, Endoscopy Safe Harbor for Forward-Looking Statements This presentation contains forward-looking
More informationElekta R&D Update 22 January 2015, Utrecht
1 Elekta R&D Update 22 January 2015, Utrecht Elekta R&D Update - 22 January 2015, Utrecht 11.00 R&D Update Niklas Savander President and CEO 11.15 Atlantic Positioning Dee Mathieson, SVP Oncology Business
More informationPROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION
Proton Therapy Edition 2016 PROTON THERAPY WORLD MARKET REPORT & DIRECTORY EDITION 2016 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/7 www.medraysintell.com Proton Therapy Edition
More informationImplementation of advanced RT Techniques
Implementation of advanced RT Techniques Tibor Major, PhD National Institute of Oncology Budapest, Hungary 2. Kongres radiološke tehnologije, Vukovar, 23-25. September 2016. Current RT equipments at NIO,
More informationElekta Innovation and Growth. ESTRO 2012 Capital Markets Presentation
Elekta Innovation and Growth ESTRO 2012 Capital Markets Presentation 15.00 Introduction Partner in cancer care Growth Tomas Puusepp President and CEO 15.30 Patient-focused development Cancer care solutions
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationItamar Medical. December Investors Presentation.
Itamar Medical December 2017. Investors Presentation. Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration
More informationRadiology Oncology Surgical Robots Market Shares, Strategies, and Forecasts, Worldwide, 2016 to 2022
Radiology Oncology Surgical Robots Market Shares, Strategies, and Forecasts, Worldwide, 2016 to 2022 Mountains of Opportunity Picture by Susan Eustis WinterGreen Research, Inc. Lexington, Massachusetts
More informationAsia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationAbout Cancer Research UK
Cancer Research UK submission to the National Assembly for Wales Health and Social Care Committee inquiry into access to medical technologies October 2013 About Cancer Research UK Every year around 300,000
More information2016 Billing and Coding Reference. Stereotactic Treatment Delivery
2016 Billing and Coding Reference Stereotactic Treatment Delivery This CY 2016 billing and coding reference is intended to be a general resource for physicians and reimbursement professionals and is current
More informationI. Equipments for external beam radiotherapy
I. Equipments for external beam radiotherapy 5 linear accelerators (LINACs): Varian TrueBeam 6, 10 & 18 MV photons, 6-18 MeV electrons, image-guided (IGRT) and intensity modulated radiotherapy (IMRT),
More informationSAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB
Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product
More informationPersonalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc
1 Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc Safe Harbor Statement This presentation contains forward-looking statements within the meaning
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationStereotactic Radiosurgery. Extracranial Stereotactic Radiosurgery. Linear accelerators. Basic technique. Indications of SRS
Stereotactic Radiosurgery Extracranial Stereotactic Radiosurgery Annette Quinn, MSN, RN Program Manager, University of Pittsburgh Medical Center Using stereotactic techniques, give a lethal dose of ionizing
More informationDelivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental
Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers
More informationAsia-Pacific Electrophysiology Market Outlook to 2020
Asia-Pacific Electrophysiology Market Outlook to 2020 Reference Code: GDMECR0114DB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationRadiation Oncology. The conf ident path to treatment Philips Radiation Oncology Solutions
Radiation Oncology The conf ident path to treatment Philips Radiation Oncology Solutions The confident path to treatment Philips Radiation Oncology Solutions Imaging Image registration Contouring Treatment
More informationChina Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020
China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationAsia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020
Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationCowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationWho Should Know Radiation Oncology Coding?
Why Should We Learn Radiation Oncology Coding? Terry Wu, Ph.D. Chief Physicist Radiation Oncology Department Willis-Knighton Cancer Center Who Should Know Radiation Oncology Coding? Radiation Oncologist
More informationProton Therapy Market Outlook - Global Analysis
Proton Therapy Market Outlook - Global Analysis Proton Therapy Market Outlook - Global Analysis BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen
More informationASX Investor Presentation
ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited
More informationRADIOTHERAPY- CURRENT SITUATION AND FUTURE TRENDS
HOSPITAL OF LITHUANIAN UNIVERSITY OF HEALTH SCIENCES KAUNO KLINIKOS RADIOTHERAPY- CURRENT SITUATION AND FUTURE TRENDS Prof. Elona Juozaitytė Perspectives of Czech- Lithuanian Research Partnerships About
More informationInvestor Day Lausanne, September 29, Nicholas Rolli Vice President, Investor Relations & Financial Communications
Investor Day Lausanne, September 29, 2016 Nicholas Rolli Vice President, Investor Relations & Financial Communications PMI Investor Relations Mobile Application ("App") / Wi-Fi Access Free app available
More information21 st Annual Needham Growth Conference
21 st Annual Needham Growth Conference Title January 15, 2019 Bonnie Anderson Chairman and Chief Executive Officer Forward-Looking Statements This presentation contains forward-looking statements, within
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationRADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS
RADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS HLC176A February 2015 Neha Maliwal Project Analyst ISBN: 1-62296-043-2 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationRevolutionizing how advanced heart disease is treated. Alexei Marko, CEO Chris Clark, CFO November 2014
Revolutionizing how advanced heart disease is treated Alexei Marko, CEO Chris Clark, CFO November 2014 Forward-Looking Statements Statements contained herein that are not based on historical or current
More informationVARIAN ONCOLOGY. RapidArc. One revolution is all it takes.
VARIAN ONCOLOGY RapidArc. One revolution is all it takes. Previous approaches to arc IMRT therapy have been restrictive. Some are limited by machine design, and deliver treatments in the axial plane only,
More informationPatrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference
Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's
More informationThe New England Journal of Medicine. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer
The New England Journal of Medicine A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer May 18, 2015 Forward-Looking Statements Various remarks that we make on this call that are
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationwww. isotopeworld.com Advanced Medical Isotope Corporation
www. isotopeworld.com Advanced Medical Isotope Corporation www. isotopeworld.com James C. Katzaroff Founder, CEO, Chairman December 5, 2016 Safe Harbor Statement This Overview contains forward-looking
More informationA New Standard of Care. ASTRO 2017 Update (NASDAQ: VRAY) 1
A New Standard of Care ASTRO 2017 Update (NASDAQ: VRAY) 1 Disclaimer Forward-Looking Statements This presentation may contain forward-looking statements that are based on our current expectations of the
More informationOPPORTUNITIES IN BRACHYTHERAPY
OPPORTUNITIES IN BRACHYTHERAPY EDITION 2014 A report written by Paul-Emmanuel Goethals & Richard Zimmermann www.medraysintell.com Brachytherapy THE FIRST COMPREHENSIVE EVALUATION OF THE BRACHYTHERAPY INDUSTRY
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationView Report Details. Global Coronary Stent Market
View Report Details Global Coronary Stent Market ------------------------------------------------- 2013 View Report Details Executive Summary Coronary heart diseases are nowadays becoming more and more
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationAnnual Stockholder Meeting May 30, confidently live life with ease
Annual Stockholder Meeting May 30, 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that
More informationBlood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, Single User License: US $ 4595
Transparency Market Research Blood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample
More informationIBA Dosimetry Company Presentation. Patient Safety & Quality Control
IBA Dosimetry Company Presentation Patient Safety & Quality Control IBA Mission Protect, enhance and save lives Protect, Enhance, and Save Lives - 2 - The History of IBA Dosimetry A story of innovation
More informationDiagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015
Diagnostics for the early detection and prevention of colon cancer Leerink Swann Global Health Care Conference February 2015 Safe Harbor Statement Certain statements made in this news release contain forward-looking
More informationRevolutionizing how advanced heart disease is treated
LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained
More informationUS Ambulatory Electrocardiography (ECG) Market: Industry Analysis & Outlook ( )
Industry Research by Koncept Analytics US Ambulatory Electrocardiography (ECG) Market: Industry Analysis & Outlook ----------------------------------------- January 2018 US Ambulatory Electrocardiography
More informationMexico Ostomy Drainage Bags Market Outlook to 2020
Mexico Ostomy Drainage Bags Market Outlook to 2020 Reference Code: GDMECC0990DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...
More informationClinical Precision for Best Cancer Care. Dee Mathieson Senior Vice President Oncology Business Line Management
Clinical Precision for Best Cancer Care Dee Mathieson Senior Vice President Oncology Business Line Management Optimizing clinical results Key drivers in modern Radiation Therapy Clinical precision Continuous
More informationYour Global Quality Assurance Platform All-in-One. All Connected. All Secure.
Your Global Quality Assurance Platform All-in-One. All Connected. All Secure. www.iba-dosimetry.com Dealing with complexity in your QA? All-in-One. Linacs OK Patients OK Reports APPROVED Satellite Center
More informationCorporate Presentation. August 2016
v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationCell Therapy. Cytori Corporate Presentation January 2012
Cytori Corporate Presentation January 2012 Safe Harbor This presentation may contain certain forward-looking statements. All statements, other than statements of historical fact, that address activities,
More informationColoplast A/S. Investor Presentation Investormøde 16. Januar 2006
Coloplast A/S Investor Presentation Investormøde 16. Januar 2006 2 Defining Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 5 areas: Ostomy
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationInvestor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region
Investor Day LA&C Region Lausanne, September 29, 2016 Jeanne Pollès President, Latin America & Canada Region Agenda Regional Overview and Performance Regional Strategies Key Markets Conclusion 2 LA&C Regional
More informationTechnique For Plan Quality and Efficiency Using VMAT Radiosurgery For Patients with Multiple Brain Metastases
Technique For Plan Quality and Efficiency Using VMAT Radiosurgery For Patients with Multiple Brain Metastases Kimberly Dempsey, BS, CMD, RT(T) Heather Smith, MS, CMD, RT(R)(T) The University of Alabama
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationFiscal 2019 Annual Meeting of Shareholders December 18, Presentation by Lori Woods, Chief Executive Officer
Fiscal 2019 Annual Meeting of Shareholders December 18, 2018 Presentation by Lori Woods, Chief Executive Officer Safe Harbor Statement Statements in this presentation about IsoRay's future expectations,
More informationA Review of Our Growth Strategies Investor Meeting June 21, 2016
1 VARIAN PROPRIETARY: INTENDED FOR INVESTORS ONLY A Review of Our Growth Strategies Investor Meeting June 21, 2016 Forward-Looking Statements Forward-Looking Statements Except for historical information,
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationASTRO DOW R. WILSON President and Chief Executive Officer 1 FOR INVESTOR USE ONLY
ASTRO 2016 DOW R. WILSON President and Chief Executive Officer 1 FOR INVESTOR USE ONLY THIS PRESENTATION IS INTENDED EXCLUSIVELY FOR INVESTORS. IT IS NOT INTENDED FOR USE IN SALES OR MARKETING. FORWARD
More informationAnalysis of the U.S. Medical Computed Tomography Imaging Systems Market
MEDICAL DEVICES PHARMACEUTICALS CHEMICALS FOOD & BEVERAGE ELECTRONICS Analysis of the U.S. Medical Computed Tomography Imaging Systems Market VPG Publications, Consulting, Clients www.vpgcorp.com VPG Market
More information